Cas No. 2778223-52-0, Cyclohexanecarboxylic acid, 1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]-, cis-

Drug  Background

Pralsetinib - a groundbreaking drug designed to revolutionize patient care. With its unparalleled efficacy and unrivaled precision, Pralsetinib unlocks new possibilities in oncology treatment. Its targeted therapy approach, specifically tailored to address genetic alterations in non-small cell lung cancer, provides a beacon of hope for patients and pharmaceutical companies alike. Offering swift response rates and manageable adverse effects, Pralsetinib holds immense potential to optimize treatment outcomes and redefine the future of cancer therapeutics. Join the vanguard of innovation and consider Pralsetinib for your portfolio.

How this intermediate is used in the synthesis of Pralsetinib?

The last step of synthesizing Pralsetinib: By reacting two Pralsetinib intermediates 2097133-17-8 and 2778223-52-0 we supply, one will get the Pralsetnib API.